COMMUNIQUÉS West-GlobeNewswire

NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
22/02/2024
WOBURN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023. The Company's mission is to [...]
Option Care Health Reports Financial Results for Fourth Quarter and Full Year 2023
22/02/2024
BANNOCKBURN, Ill., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion [...]
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023
22/02/2024
-Reported positive results from EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis (UC)- -Enrollment on target in EMERALD-2 phase 2b global randomized trial of MORF-057 in UC- -GARNET phase 2 trial of MORF-057 [...]
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
22/02/2024
WILMETTE, Ill., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced [...]
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
22/02/2024
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced [...]
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
22/02/2024
AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) Andrea Pfeifer, Ph.D., CEO to lead AC Immune- [...]
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
22/02/2024
Antagonism of the bradykinin B2 receptor via treatment with deucrictibant resulted in statistically significant reduction in rate of HAE attacks ZUG, Switzerland, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: [...]
Teleflex Announces Quarterly Dividend
22/02/2024
WAYNE, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The [...]
Aveanna Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Conference Call
22/02/2024
ATLANTA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its fourth quarter and full year results before the market open on [...]
Teleflex Reports Fourth Quarter and Full Year 2023 Financial Results
22/02/2024
WAYNE, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the fourth quarter ended December 31, 2023. Fourth quarter financial summary Revenues [...]
Curium Announces Submission of the Marketing Authorization Application for PYLCLARI®, an Innovative (18F)-PSMA PET Tracer Indicated in Adults With Prostate Cancer to Swissmedic
22/02/2024
PARIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the marketing authorization application for PYLCLARI ® (INN: Piflufolastat ( 18 F) formerly known as ( 18 F)- [...]
RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy
22/02/2024
A New Patent Granted for an Affordable and Effective Device and Method To Detect Ocular And Systemic Diseases PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ [...]
Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators
22/02/2024
STAFFORD, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is [...]
Orion and Save the Children Finland announce cooperation to promote well-being of children in Finland and globally
22/02/2024
ORION CORPORATION PRESS RELEASE 22 FEBRUARY 2024 at 11.00 EET Orion and Save the Children Finland announce cooperation to promote well-being of children in Finland and globally Orion Corporation and Save the Children [...]
Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline
22/02/2024
MELBOURNE, Australia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its results for the financial year ended 31 December 2023. All figures are in AUD$ [...]
BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026
22/02/2024
February 22, 2024 Announcement no. 03 BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026 COPENHAGEN, DENMARK and BOSTON, MA, February 22, 2024, (GLOBE NEWSWIRE) – [...]
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
22/02/2024
February 22, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]
Malaysia: Redefining Cancer Treatment Standards
22/02/2024
Embark on a Journey of Cutting-Edge Treatments and Research Collaboration KUALA LUMPUR, Malaysia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- As the world marks Cancer Awareness Month, Malaysia has made significant strides in the [...]
MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
21/02/2024
MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6 Company to Host Conference Call with Live Q&A, March 6, 2024 at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL [...]

Pages